Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Gains from Investment Securities (2024 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Gains from Investment Securities for 2 consecutive years, with -$161000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities fell 7950.0% to -$161000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$37000.0 through Dec 2025, down 311.11% year-over-year, with the annual reading at -$37000.0 for FY2025, 311.11% down from the prior year.
  • Gains from Investment Securities hit -$161000.0 in Q4 2025 for Connect Biopharma Holdings, down from $117000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $117000.0 in Q3 2025 to a low of -$161000.0 in Q4 2025.